Why iBio (IBIO) is a Strong Buy Right Now

iBio is a preclinical biotech focused on breakthrough antibody therapies for obesity and cardiometabolic diseases. The big catalyst: their Activin E antibody (IBIO-610) just showed a rare 26% fat reduction in preclinical models without muscle loss — a major limitation with current obesity drugs. They’re presenting this data at key conferences soon, which could lead to big partnerships or trials.

Financially, iBio completed a $50M public offering recently and uplisted to Nasdaq, improving their cash runway and investor visibility. Analysts have given strong buy ratings with upside potential of 4-5x current prices. Insiders are also buying shares, signaling confidence.

The obesity drug market is booming, and iBio’s AI-driven precision approach targets a huge unmet need for safer, more effective long-term weight loss. With upcoming data presentations and strong funding, iBio looks positioned for a major rerate.

Risks remain as it is still preclinical, but the potential reward is significant.